

## Number of shares and voting rights

Article L.233-8-II of Commercial Law (Code de commerce) and  
Article 223-16 of the General Regulation of the French Financial Markets Authority  
(AMF – Autorité des Marchés Financiers)

*Press release*  
Avignon, May 13<sup>th</sup>, 2013

---

**30.04.2013**

---

|   |                  |
|---|------------------|
| Total number of outstanding shares forming the capital            |                  |
| - 7,728,769 ordinary shares under ISIN FR0000054694               | 7,816,855        |
| - 88,086 shares issued from stock-options under ISIN FR0000054694 |                  |
| Number of shares with double voting rights                        | 1,001,300        |
| <b>Total number of gross voting rights</b>                        | <b>8,818,155</b> |
| Number of shares without voting rights                            |                  |
| - 8,995 bearer shares in the frame of the liquidity contract      | - 8,995          |
| <b>Total number of exercisable voting rights*</b>                 | <b>8,809,160</b> |

\*Real number of voting rights = total number of voting rights – number of shares without voting rights

If you would like to receive financial information about Naturex by e-mail, go to: [www.naturex.com](http://www.naturex.com)

Naturex has been listed on NYSE Euronext Paris, Compartment B (Mid Caps), since October 1996.



Total number of shares comprising the share capital: 7,816,855  
ISIN FR0000054694

Naturex is a component of the CAC Small and Gaïa indexes.

Naturex is eligible for "long only" Deferred Settlement Service (SRD).

Naturex established a Sponsored Level 1 American Depositary Receipt (ADR) program in the United States. Under this facility, Naturex's ADRs are traded over-the-counter in the United States under the symbol NTUXY.

SYMBOL: NRX - Reuters: NATU.PA - Bloomberg: NRX:FP - DR Symbol: NTUXY

## **About Naturex**

Naturex is the global leader in speciality plant-based natural ingredients.

The Group is organised around three strategic markets (food & beverage, nutrition & health and personal care) and produces and markets speciality plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.

Naturex's head office is based in Avignon. The company employs more than 1,300 people with high-performance manufacturing operations across 15 sites in Europe (France, Italy, Spain, the United Kingdom, Switzerland, Poland) as well as in Morocco, the United States, Brazil, Australia and India. It also has a global presence through a dedicated network of sales offices in 20 countries (France, Italy, Spain, Morocco, the United Kingdom, Belgium, Germany, Poland, Russia, U.A.E., Thailand, Japan, China, Korea, Australia, the United States, Canada, Brazil, Mexico and India).

Naturex's development is supported by positive underlying trends linked to the fast-growing demand for natural products and its capacity to provide manufacturers customised solutions to meet the requirements of their end consumers. The Group's strength lies in its positioning with specific products which constitute niche markets, supported by strong sourcing capacity and sustained research & development.

## **► Contacts**

### **Thierry Lambert**

Chairman and Chief Executive Officer  
Tel: +33 (0)4 90 23 96 89  
[t.lambert@naturex.com](mailto:t.lambert@naturex.com)

### **Thierry Bertrand Lambert**

Chief Financial Officer  
Tel: +33 (0)4 90 23 96 89  
[t.blambert@naturex.com](mailto:t.blambert@naturex.com)

### **Carole Alexandre**

Investor Relations  
Tel: +33 (0)4 90 23 78 28  
[c.alexandre@naturex.com](mailto:c.alexandre@naturex.com)

### **Anne Catherine Bonjour**

Actus Finance Press Relations  
Tel: +33 (0)1 53 67 36 93  
[acbonjour@actus.fr](mailto:acbonjour@actus.fr)